Published in Pediatr Neurol on January 01, 2006
Working memory performance among childhood brain tumor survivors. J Int Neuropsychol Soc (2012) 1.02
Predicting behavioral problems in craniopharyngioma survivors after conformal radiation therapy. Pediatr Blood Cancer (2009) 0.98
Cognitive and social functioning in children and adolescents after the removal of craniopharyngioma. Childs Nerv Syst (2010) 0.93
The utility of parent report in the assessment of working memory among childhood brain tumor survivors. J Int Neuropsychol Soc (2013) 0.92
Slower processing speed after treatment for pediatric brain tumor and acute lymphoblastic leukemia. Psychooncology (2013) 0.92
Computerized Cognitive Training for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors: A Randomized Controlled Trial. J Clin Oncol (2015) 0.88
Executive functions and social skills in survivors of pediatric brain tumor. Child Neuropsychol (2012) 0.85
Prevalence of neurobehavioral, social, and emotional dysfunction in patients treated for childhood craniopharyngioma: a systematic literature review. PLoS One (2013) 0.85
Executive dysfunction in pediatric posterior fossa tumor survivors: a systematic literature review of neurocognitive deficits and interventions. Dev Neuropsychol (2012) 0.80
Postoperative cerebral glucose metabolism in pediatric patients receiving proton therapy for craniopharyngioma. J Neurosurg Pediatr (2015) 0.75
Investigating the Role of Hypothalamic Tumor Involvement in Sleep and Cognitive Outcomes Among Children Treated for Craniopharyngioma. J Pediatr Psychol (2016) 0.75
Executive functioning profiles from the BRIEF across pediatric medical disorders: Age and diagnosis factors. Child Neuropsychol (2015) 0.75
Polysomnographic findings in craniopharyngioma patients. Sleep Breath (2017) 0.75
Neurocognitive functioning in pediatric craniopharyngioma: performance before treatment with proton therapy. J Neurooncol (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell (2010) 4.37
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun (2011) 4.07
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Early experience alters brain function and structure. Pediatrics (2004) 3.08
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell (2010) 2.80
Adolescents with d-transposition of the great arteries corrected with the arterial switch procedure: neuropsychological assessment and structural brain imaging. Circulation (2011) 2.70
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (2011) 2.53
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol (2012) 2.34
Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev (2004) 2.16
Progressive myoclonus in a child with a deep cerebellar mass. Neurology (2003) 2.16
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2012) 2.04
Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A (2005) 1.96
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell (2009) 1.92
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol (2008) 1.92
Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer (2011) 1.91
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A (2008) 1.80
Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med (2010) 1.77
Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer (2010) 1.76
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res (2008) 1.72
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics (2007) 1.67
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res (2013) 1.64
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology (2013) 1.62
Traumatic pericallosal artery aneurysm: a rare complication of transcallosal surgery. Case report. J Neurosurg (2007) 1.61
T(2) relaxometry of normal pediatric brain development. J Magn Reson Imaging (2009) 1.60
Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure. Pediatr Emerg Care (2005) 1.57
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Spontaneous occlusion of the circle of Willis in children: pediatric moyamoya summary with proposed evidence-based practice guidelines. A review. J Neurosurg Pediatr (2012) 1.56
Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol (2012) 1.56
Wound complications associated with the use of bovine serum albumin-glutaraldehyde surgical adhesive in pediatric patients. Neurosurgery (2007) 1.47
Cytologic features of pilocytic astrocytoma in cerebrospinal fluid specimens. Acta Cytol (2004) 1.46
Nasal glioma and encephalocele: diagnosis and management. Laryngoscope (2003) 1.46
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Regional brain development in serial magnetic resonance imaging of low-risk preterm infants. Pediatrics (2006) 1.43
Germinoma with malignant transformation to nongerminomatous germ cell tumor. J Neurosurg Pediatr (2010) 1.42
Cavernous malformations of the brain after treatment for acute lymphocytic leukemia: presentation and long-term follow-up. J Neurosurg Pediatr (2012) 1.40
The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg (2005) 1.39
Linear vein-based arteriovenous malformations in children. J Neurosurg Pediatr (2009) 1.38
Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol (2011) 1.36
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol (2008) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol (2008) 1.33
Symptomatic neonatal arterial ischemic stroke: the International Pediatric Stroke Study. Pediatrics (2011) 1.31
Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol (2003) 1.29
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol (2014) 1.28
PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther (2005) 1.28
The use of a laryngeal mask airway for emergent airway management in a prone child. Anesth Analg (2005) 1.28
Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol (2004) 1.26
PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol (2008) 1.22
Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization. Pediatrics (2005) 1.21
Focus on central nervous system neoplasia. Cancer Cell (2002) 1.18
INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol (2005) 1.17
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res (2005) 1.16
Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension (2011) 1.16
A novel syndrome caused by the E410K amino acid substitution in the neuronal β-tubulin isotype 3. Brain (2013) 1.15
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer (2011) 1.15
Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol (2014) 1.15
Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol (2008) 1.14
Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol (2005) 1.13
Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol (2014) 1.12
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr (2013) 1.12
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med (2011) 1.12
Surgical management of moyamoya syndrome. Skull Base (2005) 1.12
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn (2011) 1.11
miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol (2010) 1.10
Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus (2008) 1.10
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer (2010) 1.09